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Introduction {#acr23165-sec-0005}
============

Primary Sjögren\'s syndrome (SS) is an autoimmune disorder of unknown etiology that is characterized by dry eyes and dry mouth and is associated with extraglandular systemic symptoms such as fatigue, pain (myalgia and polyarthralgia), and autonomic dysfunction [1](#acr23165-bib-0001){ref-type="ref"}. It has an estimated prevalence of 0.01--0.09% [2](#acr23165-bib-0002){ref-type="ref"} and is more common in women (9:1 female:male ratio) [3](#acr23165-bib-0003){ref-type="ref"}. The condition has a marked negative impact on health‐related quality of life and social functioning [4](#acr23165-bib-0004){ref-type="ref"}.

The medications used to improve extraglandular symptoms are less effective in treating sicca symptoms [5](#acr23165-bib-0005){ref-type="ref"}. An important factor for knowledge and treatment is the weak association between the results of objective clinical tests of tear or saliva production and the severity of self‐reported dryness symptoms. This is reflected in the current America European Consensus Group (AECG) classification criteria, which dictate that a primary SS diagnosis be made when individuals fulfill 4 or more of the established criteria, which include both subjective and objective items [6](#acr23165-bib-0006){ref-type="ref"}. Understanding the discrepancy between objective and subjective findings may be of importance for improving research into the condition.

Several studies have indicated weak correlations between objective and subjective indices of ocular dryness [7](#acr23165-bib-0007){ref-type="ref"}, [8](#acr23165-bib-0008){ref-type="ref"}, [9](#acr23165-bib-0009){ref-type="ref"}, [10](#acr23165-bib-0010){ref-type="ref"}, [11](#acr23165-bib-0011){ref-type="ref"}, [12](#acr23165-bib-0012){ref-type="ref"}, [13](#acr23165-bib-0013){ref-type="ref"}, [14](#acr23165-bib-0014){ref-type="ref"}, [15](#acr23165-bib-0015){ref-type="ref"}. Although the majority of these studies found that greater subjective symptoms are associated with greater objective severity, 2 observed that lower subjective symptoms were associated with greater objective severity [7](#acr23165-bib-0007){ref-type="ref"}, [15](#acr23165-bib-0015){ref-type="ref"}, which may be related to the reduced sensation resulting from greater damage to the eye [7](#acr23165-bib-0007){ref-type="ref"}. In contrast, the relationship between subjective and objective oral dryness measures seems to be stronger [16](#acr23165-bib-0016){ref-type="ref"}, [17](#acr23165-bib-0017){ref-type="ref"}, [18](#acr23165-bib-0018){ref-type="ref"}, [19](#acr23165-bib-0019){ref-type="ref"}, [20](#acr23165-bib-0020){ref-type="ref"}, [21](#acr23165-bib-0021){ref-type="ref"}, although there are some individuals with subjective xerostomia who show no objective salivary gland dysfunction [17](#acr23165-bib-0017){ref-type="ref"}.

Discrepancies between objective and subjective symptoms create a number of dilemmas for clinicians. For example, patients may not receive optimal treatment (those with abnormal test results but few subjective symptoms may be undertreated, whereas those with normal test results but high subjective symptoms may receive interventions that are unlikely to help). Furthermore, it becomes difficult to interpret (lack of) response to treatment, which could be particularly important in clinical trials of novel therapeutic agents. It is therefore important to explore this relationship in greater depth. The path from pathologic change in tissues to perceived distressing symptoms is complex and dependent on a number of factors relating to both the severity of the underlying disease and to concomitant psychosocial factors such as low mood and anxiety [22](#acr23165-bib-0022){ref-type="ref"}, [23](#acr23165-bib-0023){ref-type="ref"}, [24](#acr23165-bib-0024){ref-type="ref"}, [25](#acr23165-bib-0025){ref-type="ref"}, [26](#acr23165-bib-0026){ref-type="ref"}. Developing a method to differentiate patients on the basis of their sensitivity to symptoms could aid research on the factors that contribute to variability in the distress and disability caused by primary SS and ultimately could contribute to the stratification of patients for particular management pathways.

The present study develops a novel method to define the degree of concordance/discrepancy between objective and subjective findings. This will be used to investigate the relationship between subjective symptoms and objective measures of dry eyes and mouth in people with primary SS to identify factors associated with symptom sensitivity.Significance & InnovationsThis study outlines a novel method for defining concordance between objective signs and subjective symptoms that is independent of units of measurement.The method can identify both stoical individuals (high objective signs and low subjective symptoms) and sensitive individuals (low objective signs and high subjective symptoms).We explored factors predicting symptom sensitivity and found that pain and fatigue symptoms were the biggest predictors of sensitivity to ocular and oral dryness, respectively.Much of the variance in symptom sensitivity remains unexplained; this method could be used in future studies to identify sensitive individuals and investigate a larger number of predictive factors (including further biologic and psychologic measures).

Patients and methods {#acr23165-sec-0006}
====================

Participants {#acr23165-sec-0007}
------------

The present study uses archive data from 688 patients in the United Kingdom Primary Sjögrenʼs Syndrome Registry database ([www.sjogrensregistry.org](http://www.sjogrensregistry.org)), who were recruited from 30 hospital sites from August 2009 to March 2012 (for full details, see Ng et al [27](#acr23165-bib-0027){ref-type="ref"}). All patients fulfilled the AECG classification criteria [6](#acr23165-bib-0006){ref-type="ref"}. Patients gave written informed consent to participate, and National Health Service ethics approval was granted for this study from the North West--Haydock National Research Ethics Service committee.

Patient‐ and clinician‐reported measures {#acr23165-sec-0008}
----------------------------------------

Subjective symptoms were assessed using the European League Against Rheumatism (EULAR) Sjögren\'s Syndrome Patient‐Reported Index (ESSPRI) sicca scores. This is a validated self‐report measure of symptoms of ocular and oral dryness [28](#acr23165-bib-0028){ref-type="ref"}, [29](#acr23165-bib-0029){ref-type="ref"}. Patients rated their symptoms over the past 2 weeks on a 0--10 scale, where 10 = maximum imaginable dryness. In addition, there were also items that measured subjective fatigue, mental fatigue, and pain. Patients also self‐reported their medication use and comorbidities.

The EuroQol 5‐dimension 3‐level scale [30](#acr23165-bib-0030){ref-type="ref"} was used to measure quality of life. It includes a simple visual analog scale (VAS) and a time tradeoff value, and lower values indicate better quality of life. Depression and anxiety were measured using the Hospital Anxiety and Depression Scale [31](#acr23165-bib-0031){ref-type="ref"}. The EULAR Sjögrenʼs Syndrome Disease Activity Index [29](#acr23165-bib-0029){ref-type="ref"}, [32](#acr23165-bib-0032){ref-type="ref"} and Disease Damage Index (ESSDDI) [33](#acr23165-bib-0033){ref-type="ref"} were used to assess the extent of systemic disease activity and damage, respectively.

### Ocular dryness {#acr23165-sec-0009}

For the Schirmer I test, a sterile strip of filter paper was inserted inside the patient\'s lower eyelid for 5 minutes, after which the level of wetting was measured using a standardized ruler. The average result of both eyes was then calculated. Participants were asked not to use eyedrops for 2 hours prior to testing. Lower scores indicate abnormal tear production and a score of ≤5 mm/5 minutes is considered severe by AECG criteria [6](#acr23165-bib-0006){ref-type="ref"}.

### Oral dryness {#acr23165-sec-0010}

To test unstimulated salivary flow (USF), the patient was required to spit saliva into a graduated test tube every minute. This was conducted at normal room temperature and humidity, and participants were asked not to eat/drink/smoke for at least 2 hours beforehand. According to AECG criteria, a quantity of ≤1.5 ml collected over 15 minutes indicates impaired saliva secretion [6](#acr23165-bib-0006){ref-type="ref"}.

Defining discordance {#acr23165-sec-0011}
--------------------

The present study used a modified discordance measure that was based on Delbaere et al (2010) [34](#acr23165-bib-0034){ref-type="ref"}. Subjective symptom severity and objective test result severity for both ocular and oral dryness were split into classes. Patients' subjective ocular and oral dryness severities (based on ESSPRI item scores) were grouped into asymptomatic (scoring 0) and symptomatic groups (5 equal classes; see Figure [1](#acr23165-fig-0001){ref-type="fig"}).

![Severity classification groups for objective results and subjective symptoms and the grid used to derive the sensitivity score. For example, an individual with severe objective test results (Schirmer \<2.5 or saliva flow \<1) but subjectively rating themselves 1 (mild) would have a discrepancy classification of −4, thereby lying at the stoical side of the distribution. An individual subjectively reporting their symptoms 9 (severe) while having a normal objective test results would score +5, at the most sensitive side of the distribution.](ACR-69-1714-g001){#acr23165-fig-0001}

Objective test result severities were grouped into the same number of classes. As no formal severity "grading" is available for either the Schirmer\'s test or USF results, reasonable severity "grading" cutoffs, supported by the expert consensus of a consulting rheumatologist (WFN), were established for the purposes of this study, and test results were grouped into equal severity classes, as shown in Figure [1](#acr23165-fig-0001){ref-type="fig"}. The severe‐class cutoffs, for both the Schirmer and USF tests, were set as close as possible to the diagnostic cutoffs used in the AECG criteria.

The subjective severity classes for ocular and oral dryness were then cross‐tabulated with the corresponding objective severity class in order to identify each patient\'s degree of sensitivity for ocular and oral dryness. This was done using the sensitivity grid shown in Figure [1](#acr23165-fig-0001){ref-type="fig"}. The disparity between subjective symptoms and objective test results was given an arbitrary value and conceptualized on a continuous sensitivity scale (Figure [2](#acr23165-fig-0002){ref-type="fig"}). On the scale, a value of 0 signifies full concordance, with negative values indicating increasing stoicism and positive values indicating increasing sensitivity. Patients were grouped into sensitive (positive sensitivity score), accurate (score of 0), and stoical (negative sensitivity score) groups.

![The sensitivity scale used in the study.](ACR-69-1714-g002){#acr23165-fig-0002}

Analysis {#acr23165-sec-0012}
--------

Analyses were performed using IBM SPSS software, version 21. Pairwise deletions for missing data were employed. One‐way analysis of variance with post hoc least significant difference tests were used to compare groups, using an alpha level of 0.05. Proportion data between groups were compared using chi‐square tests, with any significant overall difference followed up with pairwise comparisons with a Bonferroni‐adjusted *P* value equaling 0.05 / 3 = 0.017. Bivariate Spearman\'s correlations were used to explore the relationships between objective and subjective measures and between sensitivity and demographic variables, disease‐ and treatment‐related factors, and self‐ and clinician‐rated symptoms. The strength of correlations was compared using Fisher\'s r‐to‐z transformation. Linear stepwise hierarchical multiple regression was used to explore predictors of sensitivity. Variables were entered stepwise in the following sequence of blocks: first, demographics and disease factors (age, sex, symptom duration, ESSDDI score, number of comorbidities, number of medications, number of xerogenic medications, and use of a lachrymal/saliva substitute) and, second, other symptoms and quality of life (fatigue, mental fatigue, pain, anxiety, depression, and VAS assessing quality of life). The criteria for entry into the model was a *P* value less than 0.05, and for exit, a *P* value greater than 0.1. Separate regressions were run for ocular and oral sensitivity. Only the results for the variables appearing in the final model are reported.

Results {#acr23165-sec-0013}
=======

Participant characteristics and scores on the measures are shown in Table [1](#acr23165-tbl-0001){ref-type="table-wrap"}. The majority of the sample was female (n = 651, 95%). Lachrymal and saliva substitutes were used by 544 participants (79.1%) and 305 participants (44.3%), respectively. There were 295 participants (42.9%) who were taking at least 1 xerogenic medication.

###### 

Patient characteristics and variables[a](#acr23165-note-0003){ref-type="fn"}

                                           No.   Mean ± SD
  ---------------------------------------- ----- ---------------
  Demographics and illness factors               
  Age, years                               688   58.0 ± 12.5
  Disease duration, months                 661   80.1 ± 71.5
  Symptom duration, months                 686   152.4 ± 118.8
  Symptom/diagnosis gap, months            659   72.7 ± 98.6
  No. comorbidities                        688   3.6 ± 2.5
  No. medications                          688   5.7 ± 4.1
  Patient‐rated measures                         
  Ocular dryness (range 0--10)             681   5.6 ± 2.8
  Oral dryness (range 0--10)               681   6.0 ± 2.9
  Fatigue (range 0--10)                    681   5.5 ± 2.7
  Mental fatigue (range 0--10)             680   3.9 ± 2.8
  Pain (range 0--10)                       680   4.5 ± 3.0
  QoL, time tradeoff (range −1.0 to 1.0)   671   0.6 ± 0.3
  QoL, VAS (range 0--100)                  664   60.3 ± 21.4
  HADS anxiety (range 0--21)               666   8.0 ± 4.6
  HADS depression (range 0--21)            667   6.0 ± 4.0
  Clinician‐rated measures                       
  ESSDAI (range 0--123)                    687   4.8 ± 4.9
  ESSDDI (range 0--10)                     688   2.5 ± 1.9
  Objective tests                                
  Schirmer\'s test (mm/5 min)              671   6.2 ± 7.6
  Unstimulated salivary flow (ml/15 min)   688   0.9 ± 1.9
  Sensitivity                                    
  Ocular sensitivity (range −5 to +5)      681   −0.42 ± 2.2
  Oral sensitivity (range −5 to +5)        681   −1.24 ± 1.6

QoL = quality of life; VAS = visual analog scale; HADS = Hospital Anxiety and Depression Scale; ESSDAI = European League Against Rheumatism (EULAR) Sjögren\'s Sydrome Disease Activity Index; ESSDDI = EULAR Sjögren\'s Syndrome Disease Damage Index.
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Subjective versus objective symptoms {#acr23165-sec-0014}
------------------------------------

A weak but significant correlation (r = −0.13, *P* = 0.001) was found between ocular dryness and Schirmer test results. A moderate correlation (r = −0.31, *P* \< 0.001) was found between oral dryness and USF test results. The directions of the relationships indicate that greater symptom severity was associated with lower tear and saliva production. Objective and subjective results were significantly more strongly correlated for oral dryness than for ocular dryness (Z = 3.47, *P* \< 0.001).

Symptom severity and sensitivity {#acr23165-sec-0015}
--------------------------------

Figure [1](#acr23165-fig-0001){ref-type="fig"} shows the proportion of patients falling into the 6 severity classes on each of the objective measures. Forty‐six percent of patients were in the most severe range for the Schirmer test and 77% for USF, indicating that markedly reduced saliva production was more common than markedly reduced tear production. In what we defined as the normal range for the Schirmer test, there were 16% of patients, compared with only 4% for USF. Cross‐tabulating ocular and oral severity gradings showed that only 8 people (1.2%) were in the normal range on both measures, whereas 268 (39.4%) were in the most severe classification for both. In this sample, a high proportion of patients had severe symptoms on at least 1 objective test measure.

A level of discordance (i.e., a sensitivity score other than 0) was observed in 80.9% and 73.7% of the participants for ocular and oral dryness, respectively. The mean ± SD ocular sensitivity was found to be −0.42 ± 2.2 and −1.24 ± 1.6 for oral sensitivity, indicating that, on average, patients were relatively stoical for both types of dryness symptoms. Fewer patients scored in the sensitive range (≥+1) for oral dryness (n = 59, 8.7%) than for ocular dryness (n = 178, 26.8%). This is partly related to differences in the severity of objective results; the majority of patients had severely reduced saliva production and therefore could not score in the sensitive range. Sensitivity for ocular and oral dryness were positively correlated (r = 0.35, *P* \< 0.001), indicating that higher sensitivity for ocular dryness was associated with higher sensitivity for oral dryness.

Factors influencing ocular and oral dryness sensitivity {#acr23165-sec-0016}
-------------------------------------------------------

Table [2](#acr23165-tbl-0002){ref-type="table-wrap"} shows means by group for selected factors that might contribute to symptom sensitivity. The pattern was very similar for both ocular and oral sensitivity. There were no significant differences in total number of comorbidities, but oral‐stoical patients were taking significantly fewer medications (of any type) than accurate patients (*P* = 0.002). For both types of symptom sensitivity, stoical patients showed significantly less anxiety and depression and reported significantly higher quality of life than both sensitive and accurate patients (*P* \< 0.05 for all). There were no significant differences in anxiety and depression between the sensitive group and the accurate group (*P* \> 0.05 for all). There was a significant difference between the groups in the self‐reported presence of functional conditions, with the sensitive group reporting a significantly higher incidence of both fibromyalgia and irritable bowel syndrome than the stoical group (*P* \< 0.017 for all). Oral‐sensitive patients reported a significantly higher incidence of irritable bowel syndrome than accurate patients (*P* = 0.003), but otherwise there were no further significant differences between the sensitive and accurate groups. There were no significant differences between the groups in the proportion of those with any Diagnostic and Statistical Manual of Mental Disorders--defined or International Classification of Diseases--defined mental illness (*P* \> 0.05 for all).

###### 

Mean comorbidities, no. medications, and scores for depression, anxiety, and quality of life by dryness sensitivity classification. Proportions of patients in the different groups with specific comorbidities and receiving particular treatments[a](#acr23165-note-0004){ref-type="fn"}

                                      Ocular sensitivity                                   Oral sensitivity                                                                                                                                                                                                                                                                                                                                                                                                                               
  ----------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------- -------------------------------------------------
  No. comorbidities                   3.4 ± 2.3                                            3.9 ± 2.5                                            3.8 ± 2.6                                            F~2,678~ = 2.90                                           0.056                                             3.4 ± 2.3                                            3.8 ± 2.6                                            3.9 ± 2.7                                            F~2,678~ = 9.5                                            0.078
  No. medications                     5.5 ± 4.1                                            5.7 ± 3.7                                            6.3 ± 4.2                                            F~2,678~ = 2.52                                           0.081                                             5.4 ± 3.9[b](#acr23165-note-0005){ref-type="fn"}     6.6 ± 4.5[c](#acr23165-note-0006){ref-type="fn"}     5.8 ± 3.9[d](#acr23165-note-0007){ref-type="fn"}     F~2,678~ = 4.97[e](#acr23165-note-0008){ref-type="fn"}    0.007[e](#acr23165-note-0008){ref-type="fn"}
  Anxiety (HADS)                      7.3 ± 4.5[b](#acr23165-note-0005){ref-type="fn"}     8.4 ± 4.8[c](#acr23165-note-0006){ref-type="fn"}     8.9 ± 4.4[c](#acr23165-note-0006){ref-type="fn"}     F~2,661~ = 8.75[e](#acr23165-note-0008){ref-type="fn"}    \< 0.001[e](#acr23165-note-0008){ref-type="fn"}   7.3 ± 4.4[b](#acr23165-note-0005){ref-type="fn"}     9.0 ± 4.8[c](#acr23165-note-0006){ref-type="fn"}     10.2 ± 4.0[c](#acr23165-note-0006){ref-type="fn"}    F~2,661~ = 16.45[e](#acr23165-note-0008){ref-type="fn"}   \< 0.001[e](#acr23165-note-0008){ref-type="fn"}
  Depression (HADS)                   5.3 ± 3.7[b](#acr23165-note-0005){ref-type="fn"}     6.4 ± 4.3[c](#acr23165-note-0006){ref-type="fn"}     6.9 ± 4.3[c](#acr23165-note-0006){ref-type="fn"}     F~2,661~ = 11.23[e](#acr23165-note-0008){ref-type="fn"}   \< 0.001[e](#acr23165-note-0008){ref-type="fn"}   5.2 ± 3.6[b](#acr23165-note-0005){ref-type="fn"}     7.2 ± 4.4[c](#acr23165-note-0006){ref-type="fn"}     8.1 ± 4.3[c](#acr23165-note-0006){ref-type="fn"}     F~2,661~ = 24.00[e](#acr23165-note-0008){ref-type="fn"}   \< 0.001[e](#acr23165-note-0008){ref-type="fn"}
  Quality of life (VAS)               63.8 ± 20.6[b](#acr23165-note-0005){ref-type="fn"}   56.6 ± 22.5[c](#acr23165-note-0006){ref-type="fn"}   56.3 ± 21.2[c](#acr23165-note-0006){ref-type="fn"}   F~2,659~ = 10.09[e](#acr23165-note-0008){ref-type="fn"}   \< 0.001[e](#acr23165-note-0008){ref-type="fn"}   63.4 ± 20.2[b](#acr23165-note-0005){ref-type="fn"}   54.3 ± 22.5[c](#acr23165-note-0006){ref-type="fn"}   53.9 ± 22.7[c](#acr23165-note-0006){ref-type="fn"}   F~2,659~ = 14.14[e](#acr23165-note-0008){ref-type="fn"}   \< 0.001[e](#acr23165-note-0008){ref-type="fn"}
  Specific comorbidities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Fibromyalgia                        6.3[c](#acr23165-note-0006){ref-type="fn"}           8.5[d](#acr23165-note-0007){ref-type="fn"}           14.0[b](#acr23165-note-0005){ref-type="fn"}          Χ^2^(2) = 9.39[e](#acr23165-note-0008){ref-type="fn"}     0.009[e](#acr23165-note-0008){ref-type="fn"}      7.0[c](#acr23165-note-0006){ref-type="fn"}           11.2[d](#acr23165-note-0007){ref-type="fn"}          17.2[b](#acr23165-note-0005){ref-type="fn"}          Χ^2^(2) = 8.08[e](#acr23165-note-0008){ref-type="fn"}     0.018[e](#acr23165-note-0008){ref-type="fn"}
  IBS                                 5.4[c](#acr23165-note-0006){ref-type="fn"}           7.7[d](#acr23165-note-0007){ref-type="fn"}           12.0[b](#acr23165-note-0005){ref-type="fn"}          Χ^2^(2) = 7.70[e](#acr23165-note-0008){ref-type="fn"}     0.021[e](#acr23165-note-0008){ref-type="fn"}      7.7[c](#acr23165-note-0006){ref-type="fn"}           5.0[c](#acr23165-note-0006){ref-type="fn"}           17.2[b](#acr23165-note-0005){ref-type="fn"}          Χ^2^(2) = 9.13[e](#acr23165-note-0008){ref-type="fn"}     0.010[e](#acr23165-note-0008){ref-type="fn"}
  Mental illness                      3.1                                                  6.2                                                  4.0                                                  Χ^2^(2) = 2.27                                            0.321                                             2.7                                                  6.7                                                  5.2                                                  Χ^2^(2) = 5.61                                            0.061
  Treatments, %                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Xerogenic medication use            37.3[b](#acr23165-note-0005){ref-type="fn"}          46.2[d](#acr23165-note-0007){ref-type="fn"}          50.0[c](#acr23165-note-0006){ref-type="fn"}          Χ^2^(2) = 9.14[e](#acr23165-note-0008){ref-type="fn"}     0.010[e](#acr23165-note-0008){ref-type="fn"}      39.2                                                 48.6                                                 51.7                                                 Χ^2^(2) = 6.72[e](#acr23165-note-0008){ref-type="fn"}     0.035[e](#acr23165-note-0008){ref-type="fn"}
  Symptomatic treatment for dryness   97.7                                                 96.9                                                 97.5                                                 Χ^2^(2) = 0.25                                            0.883                                             97.1                                                 97.8                                                 100.0                                                Χ^2^(2) = 1.875                                           0.392
  Pilocarpine                         7.1                                                  9.2                                                  7.5                                                  Χ^2^(2) = 0.61                                            0.739                                             7.2                                                  10.1                                                 3.4                                                  Χ^2^(2) = 3.04                                            0.218
  Saliva substitute                   --                                                   --                                                   --                                                   --                                                                                                          40.1[b](#acr23165-note-0005){ref-type="fn"}          56.4[c](#acr23165-note-0006){ref-type="fn"}          43.1[d](#acr23165-note-0007){ref-type="fn"}          Χ^2^(2) = 13.83[e](#acr23165-note-0008){ref-type="fn"}    0.001[e](#acr23165-note-0008){ref-type="fn"}
  Lachrymal substitute                82.6[c](#acr23165-note-0006){ref-type="fn"}          83.1[c](#acr23165-note-0006){ref-type="fn"}          71.5[b](#acr23165-note-0005){ref-type="fn"}          Χ^2^(2) = 10.95[e](#acr23165-note-0008){ref-type="fn"}    0.004[e](#acr23165-note-0008){ref-type="fn"}      --                                                   --                                                   --                                                   --                                                        
  Punctal plugging or cauterization   18.8[b](#acr23165-note-0005){ref-type="fn"}          33.8[c](#acr23165-note-0006){ref-type="fn"}          22.0[d](#acr23165-note-0007){ref-type="fn"}          Χ^2^(2) = 12.33[e](#acr23165-note-0008){ref-type="fn"}    0.002[e](#acr23165-note-0008){ref-type="fn"}      --                                                   --                                                   --                                                   --                                                        

Values are the mean ± SD unless otherwise indicated. HADS = Hospital Anxiety and Depression Scale; VAS = visual analog scale; IBS = irritable bowel syndrome.

Significantly different from groups ‡ and § in post hoc tests (*P* \< 0.05 for continuous measures, *P* \< 0.017 for categorical measures).

Significantly different from groups † and § in post hoc tests (*P* \< 0.05 for continuous measures, *P* \< 0.017 for categorical measures).

Significantly different from groups † and ‡ in post hoc tests (*P* \< 0.05 for continuous measures, *P* \< 0.017 for categorical measures).

Statistically significant.

John Wiley & Sons, Ltd

Spearman\'s bivariate correlations were used to explore other factors associated with symptom sensitivity, and the results for both ocular and oral dryness sensitivity are shown in Table [3](#acr23165-tbl-0003){ref-type="table-wrap"}. Ocular sensitivity was weakly positively correlated with number of medications and weakly negatively correlated with age, suggesting that patients taking fewer medications and older patients were more stoical. Oral sensitivity was weakly positively correlated with number of comorbidities and number of medications, suggesting that those with fewer comorbidities and taking fewer medications were more stoical. Both types of sensitivity were moderately strongly positively correlated with patient‐rated symptoms, including fatigue, mental fatigue, pain, anxiety, and depression. The direction of the correlations indicated that those with higher levels of these symptoms were more sensitive. Both types of sensitivity were negatively correlated with quality of life, indicating that those with poorer quality of life had higher sensitivity scores.

###### 

Spearman\'s (r~s~) bivariate correlations between ocular and oral sensitivity[a](#acr23165-note-0009){ref-type="fn"}

                                    Ocular sensitivity                             Oral sensitivity
  --------------------------------- ---------------------------------------------- ----------------------------------------------
  Demographic and illness factors                                                  
  Age                               −0.11[b](#acr23165-note-0010){ref-type="fn"}   −0.02
  Disease duration                  0.02                                           0.07
  Symptom duration                  −0.00                                          0.03
  No. comorbidities                 0.07                                           0.11[c](#acr23165-note-0011){ref-type="fn"}
  No. medications                   0.10[c](#acr23165-note-0011){ref-type="fn"}    0.12[c](#acr23165-note-0011){ref-type="fn"}
  Patient‐rated measures                                                           
  Fatigue                           0.38[b](#acr23165-note-0010){ref-type="fn"}    0.39[b](#acr23165-note-0010){ref-type="fn"}
  Mental fatigue                    0.33[b](#acr23165-note-0010){ref-type="fn"}    0.30[b](#acr23165-note-0010){ref-type="fn"}
  Pain                              0.33[b](#acr23165-note-0010){ref-type="fn"}    0.29[b](#acr23165-note-0010){ref-type="fn"}
  Quality of life, time tradeoff    −0.25[b](#acr23165-note-0010){ref-type="fn"}   −0.24[b](#acr23165-note-0010){ref-type="fn"}
  Quality of life, VAS              −0.21[b](#acr23165-note-0010){ref-type="fn"}   −0.28[b](#acr23165-note-0010){ref-type="fn"}
  HADS anxiety                      0.20[b](#acr23165-note-0010){ref-type="fn"}    0.26[b](#acr23165-note-0010){ref-type="fn"}
  HADS depression                   0.22[b](#acr23165-note-0010){ref-type="fn"}    0.30[b](#acr23165-note-0010){ref-type="fn"}
  Clinician‐rated measures                                                         
  ESSDAI                            0.02                                           0.03
  ESSDDI                            −0.07                                          0.05
  Oral sensitivity                  0.35[b](#acr23165-note-0010){ref-type="fn"}    --

VAS = visual analog scale; HADS = Hospital Anxiety and Depression Scale; ESSDAI = European League Against Rheumatism (EULAR) Sjögren\'s Syndrome Disease Activity Index; ESSDDI = EULAR Sjögren\'s Syndrome Disease Damage Index.

*P* ≤ 0.001.

*P* from 0.001 to ≤ 0.01.

John Wiley & Sons, Ltd

Relationship between treatment and symptom sensitivity {#acr23165-sec-0017}
------------------------------------------------------

Patients in the different sensitivity classes receiving treatment were examined in order to explore relationships between symptom sensitivity and treatment received (Table [2](#acr23165-tbl-0002){ref-type="table-wrap"}). Ocular‐stoical patients were significantly less likely to be receiving a medication known to cause dryness than sensitive patients (*P* = 0.004), and while there was an overall group difference for oral sensitivity, post hoc tests did not show any significant differences between the groups. There were no significant differences between the groups in the use of at least 1 symptomatic treatment for dryness or pilocarpine (*P* \> 0.218 for all). However, oral stoics were significantly less likely to be using a saliva substitute (40.1%) than accurate patients (56.4%; *P* \< 0.001), and there was no significant difference between stoical and sensitive patients (43.1%; *P* = 0.660). Similarly for ocular sensitivity, ocular stoics were significantly less likely than accurate patients to have received the more invasive treatments of punctal plugging or cauterization (18.8% versus 33.8%; *P* = 0.012), and there were no differences in ocular‐sensitive patients (22.0%; *P* = 0.367). Ocular‐sensitive patients were significantly less likely to be using a lachrymal substitute than both the accurate and stoical patients (71.5% versus 83.1% and 82.6%, respectively; *P* = 0.016 and *P* = 0.002, respectively).

Regression analysis {#acr23165-sec-0018}
-------------------

### Ocular dryness {#acr23165-sec-0019}

The final model contained 6 predictor variables and was statistically significant (F~6,628~ = 21.8, *P* \< 0.001), explaining 16.5% of the variance in sensitivity (Table [4](#acr23165-tbl-0004){ref-type="table-wrap"}). The statistically significant predictors in the final model were age, ESSDDI score, pain, fatigue, and mental fatigue. Pain explained the largest additional variance (10%) of all the predictors, and fatigue was the next highest (2.3%). Age and ESSDDI score were both negatively related to sensitivity, indicating that older patients and those with greater disease damage tended to be less sensitive.

### Oral dryness {#acr23165-sec-0020}

The final model contained 6 predictor variables and was statistically significant (F~6,628~ = 24.1, *P* \< 0.001) explaining 17.9% of the variance in sensitivity (Table [4](#acr23165-tbl-0004){ref-type="table-wrap"}). The statistically significant predictors in the final model were use of a saliva substitute, fatigue, and depression, all of which were positively associated with greater sensitivity. Level of fatigue explained the largest additional variance (11.7%), indicating that those with higher fatigue tended to be more sensitive.

###### 

Stepwise hierarchical regression summary for ocular dryness sensitivity and oral dryness sensitivity[a](#acr23165-note-0012){ref-type="fn"}

  Model                        Adj. R^2^ (%)   ΔR^2^ (%)   Standardized β   Test‐statistic    *P*
  ---------------------------- --------------- ----------- ---------------- ----------------- -------------------------------------------------
  Ocular dryness sensitivity                                                                  
  Overall model                16.5            --          --               F~6,628~ = 21.8   \< 0.001[b](#acr23165-note-0013){ref-type="fn"}
  Age                                          1.3         −0.09            t~634~ = −2.39    0.017[c](#acr23165-note-0014){ref-type="fn"}
  No. medications                              1.9         0.01             t~634~ = 0.25     0.802
  ESSDAI                                       0.5         −0.08            t~634~ = −2.23    0.026[c](#acr23165-note-0014){ref-type="fn"}
  Pain                                         10.0        0.19             t~634~ = 3.89     \< 0.001[b](#acr23165-note-0013){ref-type="fn"}
  Fatigue                                      2.3         0.16             t~634~ = 2.95     0.003[b](#acr23165-note-0013){ref-type="fn"}
  Mental fatigue                               0.5         0.11             t~634~ = 2.14     0.033[c](#acr23165-note-0014){ref-type="fn"}
  Oral dryness sensitivity                                                                    
  Overall model                17.9            --          --               F~6,628~ = 24.1   \< 0.001[b](#acr23165-note-0013){ref-type="fn"}
  Use of saliva substitute     --              2.9         0.15             t~634~ = 3.99     \< 0.001[b](#acr23165-note-0013){ref-type="fn"}
  No. comorbidities            --              1.3         0.02             t~634~ = 0.43     0.667
  Age                          --              0.6         −0.01            t~634~ = −0.21    0.831
  Xerogenic medications        --              0.5         0.01             t~634~ = 0.24     0.812
  Fatigue                      --              11.7        0.30             t~634~ = 6.88     \< 0.001[b](#acr23165-note-0013){ref-type="fn"}
  Depression                   --              0.9         0.13             t~634~ = 2.91     0.004[b](#acr23165-note-0013){ref-type="fn"}

Adj. = adjusted; ESSDAI = European League Against Rheumatism Sjögren\'s Sydrome Disease Activity Index.

*P* ≤ 0.001.

*P* \> 0.001 and ≤0.05.

John Wiley & Sons, Ltd

Discussion {#acr23165-sec-0021}
==========

As in other studies, subjective dryness symptoms and objective test results were only weakly correlated in patients with primary SS. A novel method for quantifying the discrepancy between subjective and objective symptoms was devised, as an ordinal scale of symptom sensitivity, ranging from stoical (self‐reported dryness at a relatively low level compared to objective findings) to accurate to sensitive (self‐reported dryness at a relatively high level compared to objective findings). The majority of patients had a relatively stoical presentation. A significant moderate association was observed between ocular and oral dryness sensitivity, indicating that those who tended to be sensitive to ocular dryness also tended to be sensitive to oral dryness. Comparisons of sensitive, stoical, and accurate patients showed that stoical patients had lower depression and anxiety scores than the other groups, but they were also less likely to have received some treatments than accurate patients (saliva substitute and punctal plugging or cauterization). Sensitive patients were not more likely to receive higher levels of intervention than accurate or stoical patients, but a greater proportion of them reported functional conditions (fibromyalgia and irritable bowel syndrome). In regression analyses, symptom sensitivity was predicted by a variety of factors, but pain (ocular sensitivity) and fatigue (oral sensitivity) explained the most variance.

As found in other studies, the relationship between subjective and objective measures was weaker for ocular dryness than for oral dryness [35](#acr23165-bib-0035){ref-type="ref"}, [36](#acr23165-bib-0036){ref-type="ref"}, [37](#acr23165-bib-0037){ref-type="ref"}. Ocular dryness sensitivity was predicted by greater pain and fatigue, whereas age and disease damage were significant negative predictors, suggesting that older patients and those with more severe disease are relatively more stoical. Adatia et al [7](#acr23165-bib-0007){ref-type="ref"} suggested that symptom perception may be diminished by reduced corneal sensation due to more severe illness, which may explain the negative relationship with disease damage. This may be part of the explanation for why subjective and objective ocular dryness measures correlate relatively more weakly; a straightforward, linear relationship between severity of disease and severity of subjective symptoms would not be expected. Additionally, there were fewer patients whose objective test results fell in the severe range for tear production (46%) compared to saliva production (77%), and 16% had objectively normal tear production (compared to only 4% for saliva production), leaving more scope to identify ocular patients as sensitive. The symptom of dry eye is less well‐defined than dry mouth and may be used to refer to a myriad of ocular sensations, including burning pain, grittiness, and tired or heavy eyes. This introduces heterogeneity in patients, in terms of what they mean when they report having dry eyes, and not all of the experienced sensations can be expected to relate to tear production. As "dry eye" often refers to painful sensations in the eye, this may explain why self‐reported pain was the greatest predictor of ocular sensitivity (but was not a significant predictor of oral sensitivity).

In contrast, sensitivity to oral dryness symptoms was most strongly associated with global fatigue, followed by use of a saliva substitute and number of comorbidities. It was not related to disease severity or pain. This suggests that different processes are related to symptom sensitivity to different symptoms. The overall proportion of variance explained in both regression models (i.e., 16.5--17.9%) indicates that there are explanatory factors that were not included in the present study, which should be explored in future studies. Biologic factors relating to the composition of the tears or saliva may be relevant. Xerostomia can be affected by saliva composition [38](#acr23165-bib-0038){ref-type="ref"}, and multiple factors, such as lachrymal secretion, corneal damage, tear film stability, and the chemical properties of tears all jointly affect the perception of ocular dryness [39](#acr23165-bib-0039){ref-type="ref"}. Relatively sensitive individuals could be targeted in future research to identify biologic markers in tears or saliva that may affect perceived dryness.

Psychologic models of symptom perception propose a large number of factors that may impact on whether someone notices a symptom [26](#acr23165-bib-0026){ref-type="ref"} and could be of relevance to measure in PSS. Trait characteristics such as neuroticism, alexithymia (the ease with which one identifies emotions), and distress tolerance may play a role [40](#acr23165-bib-0040){ref-type="ref"}, [41](#acr23165-bib-0041){ref-type="ref"}. It has been shown that catastrophization (a manner of thinking that exaggerates worries and amplifies negative consequences) [42](#acr23165-bib-0042){ref-type="ref"} is highly predictive of pain severity in patients with primary SS [43](#acr23165-bib-0043){ref-type="ref"}. Similarly, greater body‐focused attention may contribute to symptom‐noticing [44](#acr23165-bib-0044){ref-type="ref"}, and somatosensory amplification (a heightened responsiveness to sensory stimulation) has been shown to contribute to the symptoms of many rheumatic conditions [41](#acr23165-bib-0041){ref-type="ref"}. Geisser et al [45](#acr23165-bib-0045){ref-type="ref"} found that amplification in chronic fatigue syndrome and fibromyalgia was related to higher clinical pain and larger numbers of comorbid somatic symptoms and, consistent with this finding, we identified a greater proportion of patients with fibromyalgia in the sensitive groups. Anxiety and depression have also been shown to be significantly related to greater sensitivity. In a population‐based study by Anttila et al [22](#acr23165-bib-0022){ref-type="ref"}, participants with subjective dry mouth had depressive symptoms in significantly higher frequencies. Similarly, Kim et al [24](#acr23165-bib-0024){ref-type="ref"} concluded that depression was associated with dry eye symptoms in participants with normal Schirmer test results. Additionally, social, contextual, cultural, and interpersonal factors likely also contribute to how and whether patients openly discuss their symptoms with their doctor, making it difficult to determine, particularly for stoical patients, whether they do not experience distressing symptoms or they simply do not report them.

The strengths of this study include the large sample of primary SS patients and the novel method for defining sensitivity, which allowed potential associated variables to be investigated. However, there are a number of limitations. First, self‐report methods are prone to response bias, such as demand characteristics bias, social desirability bias, and recall bias [46](#acr23165-bib-0046){ref-type="ref"}. Furthermore, when completing the self‐report measure, participants judged the severity of their sicca symptoms against their own standards; however, the severity of objective measures is judged against standards formulated from the results of many individuals, so a degree of discrepancy could be expected. Second, only 1 objective measure of ocular and oral dryness was used. USF is the test of choice for assessing salivary secretion [20](#acr23165-bib-0020){ref-type="ref"}; however, variations of methods exist for measuring ocular dryness. While the Schirmer I test is a valid assessment, issues regarding reproducibility and sensitivity have been reported [47](#acr23165-bib-0047){ref-type="ref"}, and its use without anesthesia (as in the present study) includes both basal and reflex lachrymal secretion [48](#acr23165-bib-0048){ref-type="ref"}, which may exaggerate the severity of objective ocular dryness in those with progressive corneal desensitization.

Categories of objective symptoms were derived specifically for this study, in order to calculate the sensitivity score. While the expert opinion of a consulting rheumatologist was used in developing the categories and exploratory work using different cutoff scores or different ways of categorizing patients showed the same pattern of relationships, the categories used here need further empirical support and replication in future studies to determine whether or not they can be operationalized and used clinically.

Going forward, we advocate the use of a measure of objective‐subjective symptom discordance, such as that outlined here, to facilitate illness stratification to allow for further research into the reasons behind this. Of particular interest are the groups with the greatest discordance, i.e., patients reporting severe subjective symptoms despite being at the milder end of the objective symptom distribution, and those reporting mild subjective symptoms despite being at the severe end of the objective distribution. An exploration of potential physical and psychologic explanations for this phenomenon is warranted. For example, is there a difference in pathophysiology that might contribute to the increased experience of mildly abnormal objective symptoms, such as tear and saliva composition, changes in corneal sensitivity, or genetic differences in, for example, pain sensitivity? Conversely, there is detailed literature on the psychologic aspects of interoception and pain perception. Applying some of the methodologies from this literature to develop our understanding of the individual differences in the felt experience of physical symptoms would allow us to explore alternative treatment options, such as cognitive--behavioral therapy or mindfulness for those with lower symptom tolerance/higher subjective symptom distress [49](#acr23165-bib-0049){ref-type="ref"}, [50](#acr23165-bib-0050){ref-type="ref"}, [51](#acr23165-bib-0051){ref-type="ref"}.

In conclusion, the study developed a novel method for determining symptom sensitivity. Discrepancies between objective measures and subjective symptoms were most strongly related to pain and fatigue; however, multiple interrelated psychologic, pathophysiologic, and environmental factors are likely involved. Limitations associated with accurately measuring dry eyes/mouth both subjectively and objectively may also contribute to the observed discrepancies. Stratifying patients by symptom sensitivity for further research will improve our understanding of factors that have an impact on distress caused by symptoms and could open the door to nonmedication‐based treatments for a subgroup of patients with the most sensitivity to symptoms.
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